Overview
- Thermo Fisher reported second‑quarter revenue of $11.99 billion and adjusted earnings of $6.03 per share, beating analysts’ estimates on both the top and bottom lines on Thursday, July 23.
- Organic revenue grew about 5% year over year, driven by broad strength across businesses rather than a single product or market.
- Laboratory Products & Biopharma Services generated roughly $6.69 billion, up near 12%, and Life‑Sciences Solutions produced about $2.82 billion, up roughly 13%, reflecting gains in clinical trial support and research tools.
- Management raised full‑year 2026 guidance to $24.93–$25.33 in adjusted EPS and $47.4 billion–$48.1 billion in revenue, and the company returned capital by repurchasing $1.0 billion of stock while announcing plans to divest its microbiology business.
- Thermo Fisher also highlighted new offerings and capacity moves, including next‑generation Orbitrap instruments with AI analytics and a Bioprocess Design Center in Plainville, Massachusetts, and the results helped lift the stock and ease sector worries after a peer’s weaker outlook.